MINI FUTURE LONG - ZEALAND PHARMA | Market Closed - Börse Stuttgart 19:00:43 23/05/2024 BST | ||
| 6.71 EUR | -1.03% |
|
| Current month | -4.24% | ||
| 1 month | +7.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 6.71 | -1.03% |
| 22/05/24 | 6.78 | -3.00% |
| 21/05/24 | 6.99 | +5.75% |
| 20/05/24 | 6.61 | -0.90% |
| 17/05/24 | 6.67 | -2.34% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 07:00 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MB1FVD |
| ISIN | DE000MB1FVD9 |
| Date issued | 15/12/2022 |
| Strike | 99.35 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.41 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.8 € |
|---|---|
| Lowest since issue | 1.38 € |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
603
DKK
Average target price
785.6
DKK
Spread / Average Target
+30.28%
- Stock Market
- Certificates
- Certificat
